The usage of Slrig1, a negative regulator of the oncogenic epidermal growth factor receptor (EGFR) family, disrupted downstream signalling in both wild-type and constitutively active EGFR mutated glioma cells (EGFRvIII) in vitro and in vivo. The gene discussed is EGFR; the disease is glioma.